此应用程序的某些内容目前无法使用。
如果这种情况持续存在,请联系我们反馈与联系
1. (GB2531093) Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
注:相关文本通过自动光符识别流程生成。凡涉及法律问题,请以 PDF 版本为准
CLAIMS
1.         Cannabidiol (CBD) for use in the treatment of epilepsy, wherein the epilepsy is a
treatment-resistant epilepsy (TRE), and wherein the CBD is present in an amount that reduces total convulsive seizure frequency by greater than 50% with respect to the seizure frequency achieved on concomitant anti-epileptic drugs (AED).
2.         CBD for use according to claim 1, wherein the CBD is used in combination with two or more concomitant anti-epileptic drugs (AED).
3.         CBD for use according to claim 1 or claim 2, wherein the type of treatment-resistant epilepsy is Dravet syndrome, myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES).
4.         CBD for use according to claim 3, wherein the seizure type to be treated is a complex partial seizure (focal seizure with impairment).
5.         CBD for use according to any of the preceding claims, wherein the CBD is present in an amount that reduces total convulsive seizure frequency by greater than 70% with respect to the seizure frequency achieved on concomitant anti-epileptic drugs (AED).
6.         CBD for use according to any of the preceding claims, wherein the CBD is present in an amount that reduces total convulsive seizure frequency by greater than 90% with respect to the seizure frequency achieved on concomitant anti-epileptic drugs (AED).
7.         CBD for use according to any of the preceding claims, wherein the CBD is present in an amount that reduces total convulsive seizure frequency by 100% with respect to the seizure frequency achieved on concomitant anti-epileptic drugs (AED).
8.         CBD for use according to any of the preceding claims, wherein the CBD is present as a highly purified extract of cannabis which comprises at least 98% (w/w) CBD.
9.         CBD for use according to claim 2, wherein the one or more AED is selected from the group consisting of: clobazam; levetiracetam; topiramate; stiripentol; phenobarbital; lacsamide; valproic acid; zonisamide; perampanel; and fosphenytoin.
10.       CBD for use according to claim 9, wherein one of the AED is clobazam.
11.       CBD for use according to any of the preceding claims, wherein the number of different anti-epileptic drugs that are used in combination with the CBD is reduced.
CBD for use according to any of the preceding claims, wherein the dose of anti-epileptic drugs that are used in combination with the CBD is reduced.
CBD  for use according claim 11 , wherein the dose of AED which is reduced is of clobazam.
CBD  for use according to any of the preceding claims, wherein the dose of CBD is from 5 mg/kg/day to 25 mg/kg/day.
A  method of treating treatment-resistant epilepsy comprising administering cannabidiol (CBD) to a patient in an amount sufficient to reduce total convulsive seizure frequency by greater than 50% with respect to the seizure frequency achieved on one or more concomitant anti-epileptic drugs (AED).